Correction to : Graefe’s Archive for Clinical and Experimental Ophthalmology (2022) 260:3489–3498
10.1007/s00417-022-05703-9
This article contained some errors:
#1. In Table 1, the direction of the inequality sign in the logMAR Best-corrected visual acuity was reversed.
Table 1.
Patient characteristics at baseline
| Safety analysis set (n = 646) | |
|---|---|
| Male, n (%) | 405 (62.7) |
| Age, years | |
| Mean ± SD | 64.9 ± 11.2 |
| Median (range) | 66.0 (26–89) |
| Stage of diabetic retinopathy, n (%) | |
| Simple diabetic retinopathy | 156 (24.1) |
| Pre-proliferative diabetic retinopathy | 275 (42.6) |
| Proliferative diabetic retinopathy | 173 (26.8) |
| Unknown | 42 (6.5) |
| Duration of diabetes mellitus, years, n (%) | |
| < 5 | 26 (4.0) |
| ≥ 5, < 10 | 61 (9.4) |
| ≥ 10 | 196 (30.3) |
| Unknown | 363 (56.2) |
| HbA1c, n (%) | |
| ≤ 7.0% | 65 (10.1) |
| > 7.0% | 68 (10.5) |
| Unknown | 513 (79.4) |
| Extent of edema, n (%) | |
| Diffuse | 417 (64.6) |
| Localized | 194 (30.0) |
| Other | 1 (0.2) |
| Unknown | 34 (5.3) |
| Best-corrected visual acuity, logMAR | |
| Mean ± SD | 0.441 ± 0.364 |
| Median (range) | 0.349 (− 0.08 to 2.00) |
| Best-corrected visual acuity, decimal, n (%) | |
≤ 0.5 (logMAR
0.3) |
410 (63.5) |
| > 0.5 | 236 (36.5) |
| Central retinal thickness, μm (n = 453) | |
| Mean ± SD | 441.2 ± 134.6 |
| Median (range) | 432.0 (108–869) |
| Prior treatment, n (%) | |
| No | 166 (25.7) |
| Yes | 471 (72.9) |
| Unknown | 9 (1.4) |
| Medical history | |
| Ocular | 270 (41.8) |
| Non-ocular | 135 (20.9) |
| Combination therapies, n (%) | |
| No | 434 (67.2) |
| Yes | 201 (31.1) |
| Unknown | 11 (1.7) |
LogMAR logarithm of the minimum angle of resolution, SD standard deviation
#2. Regarding Supplementary Information 4, the patients who received combination therapies were corrected in accordance with the communication with the Pharmaceuticals and Medical Devices Agency. Although there were additions in some categories, these additional patients also had received other combination therapies, thus there was no change in the total number of patients receiving the combination therapies.
#3. Regarding “Events that occurred when used in combination with PRP” in Table 3, the proportion of the number of patients who developed these events was originally calculated using the safety analysis set (n = 646) as a denominator, but this time, the number of the patients who received PRP (n = 81) as combination therapy was used as a denominator. In addition, we recounted the number of patients who developed these adverse events by distinguishing between serious and non-serious.
Table 3.
Safety specifications: incidence of adverse events and adverse drug reactions
Medical Dictionary for Regulatory Activities terms for each type of event are listed in Supplementary Information 1
PRP panretinal photocoagulation
*Including patients with multiple events
#4. In the footnote of Fig. 2, we had mistakenly put the text that should have been included in the footnote of Supplementary information 8.
Fig. 2.
a LogMAR BCVAs and numbers of patients during the 24-month study period. b CRTs (μm) and numbers of patients during the 24-month study period. The mean and standard deviation are indicated with markers and whiskers, respectively. BCVA best-corrected visual acuity, BL baseline, CRT central retinal thickness, logMAR logarithm of the minimum angle of resolution
The correct tables and legends are shown below. Revisions are shown in green.
Supplementary Information 4 Combination therapiesa
| Patients, n (%)b | |
|---|---|
| Safety analysis set | 646 (100) |
| Absence of combination therapies | 434 (67.2) |
| Presence of combination therapiesa | 201 (31.1) |
| Panretinal photocoagulation |
|
| Corticosteroids |
|
| Surgery | 52 (8.0) |
| Direct coagulation | 45 (7.0) |
| Grid coagulation | 3 (0.5) |
| Other | 10 (1.5) |
aDrug treatment other than IVT-AFL, photocoagulation or surgery, performed for DME after the first dose of IVT-AFL
bCounted under all applicable categories
Table 3
Figure 2
Supplementary Information 8 Subgroup analysis based on the presence/absence of previous treatment. (a) LogMAR BCVAs and numbers of patients during the 24-month study period.
(b) CRTs (μm) and numbers of patients during the 24-month study period.
The mean and standard deviation are indicated with markers and whiskers, respectively.
BCVA best-corrected visual acuity; BL baseline; CRT central retinal thickness; logMAR logarithm of the minimum angle of resolution
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.